Company profile
TVARDI THERAPEUTICS, INC.
NASDAQ:TVRDBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| TTI-101 | phase2 | — | 4 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05440708 | phase1_2 | recruiting | 2023-03-23 | 2027-02-01 | Tvardi Therapeutics, Incorporated | A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma |
| NCT03195699 | phase1 | completed | 2017-11-15 | 2024-06-24 | Tvardi Therapeutics, Incorporated | Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers |
| NCT05384119 | phase1 | terminated | 2023-01-09 | 2024-05-06 | Tvardi Therapeutics, Incorporated | Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer |
| NCT05671835 | phase2 | completed | 2023-05-15 | 2025-08-14 | Tvardi Therapeutics, Incorporated | Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis |
FDA applications (0)
No records yet.